Research Analysts Offer Predictions for ATXS FY2024 Earnings

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Research analysts at HC Wainwright lifted their FY2024 earnings estimates for shares of Astria Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($1.74) per share for the year, up from their previous estimate of ($1.82). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q4 2024 earnings at ($0.50) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($1.88) EPS, FY2027 earnings at ($1.93) EPS and FY2028 earnings at ($1.62) EPS.

A number of other equities research analysts also recently commented on ATXS. TD Cowen assumed coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They issued a “buy” rating and a $35.00 target price for the company. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday, August 13th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Finally, Oppenheimer raised their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Stock Down 2.2 %

ATXS opened at $9.16 on Monday. The stock has a market capitalization of $516.94 million, a price-to-earnings ratio of -4.38 and a beta of 0.71. The firm has a 50 day moving average price of $11.36 and a 200-day moving average price of $10.62. Astria Therapeutics has a twelve month low of $4.41 and a twelve month high of $16.90.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC grew its stake in shares of Astria Therapeutics by 70.5% during the 3rd quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock valued at $1,020,000 after acquiring an additional 38,321 shares during the period. Wellington Management Group LLP lifted its holdings in Astria Therapeutics by 8.7% during the third quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock valued at $1,624,000 after purchasing an additional 11,763 shares in the last quarter. RA Capital Management L.P. boosted its position in shares of Astria Therapeutics by 1.2% in the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after purchasing an additional 61,457 shares during the period. Redmile Group LLC bought a new position in shares of Astria Therapeutics in the third quarter worth approximately $3,423,000. Finally, Patient Square Capital LP purchased a new stake in shares of Astria Therapeutics in the third quarter worth $434,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.